Effect of intraduodenally administered histamine on gastric acid secretion in rats and guinea pigs

Endogenous histamine reduces plasma insulin-like growth factor I via H1 receptor-mediated pathway in the rat

Endotoxin has been recently shown to reduce plasma insulin-like growth factor I. As it was reported that histamine can induce gut-derived endotoxemia, we wanted to determine whether histamine has a similar effect on plasma insulin-like growth factor I. Compound 48/80 (a histamine releaser) was injected subcutaneously into rats, then blood was taken for plasma insulin-like growth factor I assay and the livers were assayed for insulin-like growth factor I mRNA. Like endotoxin, injection of compound 48/80 significantly reduced plasma insulin-like growth factor I. Six hours post-injection, plasma insulin-like growth factor I was reduced by 61% (P < 0.001), and 24 h post-injection, it was still lower (by 35% P < 0.001) than in the control group. Hepatic insulin-like growth factor I mRNA was not reduced by this treatment. The effect of compound 48/80 on plasma insulin-like growth factor I was significantly attenuated by oral administration of the histamine H1 receptor antagonist (chlorpheniramine), but not by the histamine H2 receptor antagonists (cimetidine and ranitidine). Oral administration of polymyxin B (an antiendotoxin antibiotic) did not attenuate the effect of compound 48/80 on plasma insulin-like growth factor I at all. In conclusion, endogenous histamine reduces plasma insulin-like growth factor I via H1 receptor-mediated pathway. Our study suggests a novel role of histamine in the regulation of insulin-like growth factor I metabolism in vivo.

Methicillin-resistant Staphylococcus aureus proliferation in the rat gut is influenced by gastric acid inhibition and the administration of antibiotics

The author studied methicillin-resistant Staphylococcus aureus (MRSA) proliferation in the rat gut which was influenced by gastric acid inhibition and the administration of antibiotics. When male Wistar rats were bred by total parenteral nutrition (TPN), and were continuously administered famotidine 4 mg/kg per day, the gastric acidity was observed to decrease to pH 6.4+/-0.1. However, when they were bred by TPN, and histamine 4 mg/kg per hour was continuously administered, the gastric acidity was observed to increase to pH 1.9+/-0.4. MRSA was thus able to cross over to the small intestine only during the famotidine medication. If rats were intravenously administered latamoxef (LMOX) after an oral inoculation of MRSA, then the viable MRSA counts in the stomach, small intestine, and large intestine all decreased on day 4. In contrast, if the gastric acidity decreased and the rats were treated by an oral administration of kanamycin and metronidazole before an oral inoculation of MRSA and thereafter were administered LMOX, then the MRSA count significantly increased. It is thus concluded that a suppression of gastric acid and a great disorder of the intestinal flora is indispensable for the colonization of MRSA into the small intestine, while in vitro the propagation of MRSA requires a continuity of suppression absent in the bacterial flora.

Histidine and histamine metabolism in rat enterocytes

To study the metabolic fate of L-histidine and histamine in rat isolated enterocytes, enterocytes were incubated in the presence of 0.1 mM L-[U-14C] histidine. At the rate of 11.1 +/- 2.7 pmol/10(6) cells/30 min, the amino acid was incorporated into cellular proteins. 80 microM cycloheximide, i.e. a protein synthesis inhibitor, inhibited this incorporation by 70 +/- 17%. L-histidine was used for cellular protein synthesis which depended on time and concentration. 0.1 mM L-[U-14C] histidine was little oxidized by intestinal cells, i.e. 0.12 +/- 0.06 pmol/10(6) cells/30 min, and was not converted into histamine. When 10 mM histamine was added to the incubation medium, it completely inhibited the incorporation of 0.1 mM [1,4-14C] putrescine into isolated enterocytes. In enterocyte homogenates, this corresponded to inhibition by histamine of putrescine incorporation as catalyzed by transglutaminase activity. Since histamine incorporation into TCA-precipitable material derived from enterocyte homogenates depended on time and concentration, we concluded that exogenous, but not de novo-formed histamine was able to compete with putrescine incorporation into enterocytes as catalyzed by transglutaminase activity.

Novel effects of histamine on lipoprotein metabolism: suppression of hepatic low density lipoprotein receptor expression and reduction of plasma high density lipoprotein cholesterol in the rat

Histamine has been shown to be involved in atherosclerosis and coronary heart disease. Little information is available regarding the effects of histamine on lipoprotein metabolism. In the current study, we investigated the effects of histamine on the expression of hepatic low density lipoprotein (LDL) receptors and on plasma lipoproteins in the rat. Injection of compound 48/80 (C48/80, a histamine releaser) or histamine reduced hepatic LDL receptor expression, but not LDL receptor messenger RNA levels. Oral administration of polymyxin B (an antiendotoxin antibiotic and a histamine releaser) before the injection of C48/80 or histamine did not attenuate their effects. Polymyxin B itself had effects similar to those of C48/80 and histamine on LDL receptors. These results suggest that the effects of histamine are not mediated by the induction of gut-derived endotoxemia. Histamine H2 agonists (dimaprit and impromidine), but not H1 agonists (2-methylhistamine and 2-thiazolylethylamine), also reduced hepatic LDL receptor expression. The suppressive effect of C48/80 on hepatic LDL receptor expression was not attenuated by either the H1 antagonist (chlorpheniramine) or the H2 antagonist (cimetidine). Administration of C48/80 also reduced plasma high density lipoprotein (HDL) cholesterol. The H1 antagonist (chlorpheniramine), but not the H2 antagonist (cimetidine), almost completely reversed the effect of C48/80 on plasma HDL cholesterol. In conclusion, histamine suppresses hepatic LDL receptor expression via a non-H1 receptor-mediated pathway, and histamine reduces plasma HDL cholesterol via an H1 receptor-mediated pathway.